

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

APC/Cyanine7 anti-mouse CD3

RRID:AB_2242784

Type: Antibody

Proper Citation

BioLegend Cat# 100222, RRID:AB_2242784

Antibody Information

URL: http://antibodyregistry.org/AB_2242784

Proper Citation: BioLegend Cat# 100222, RRID:AB_2242784

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2242784

Vendor: BioLegend

Catalog Number: 100222

Alternative Catalog Numbers: 100221

Record Creation Time: 20250820T025626+0000

Record Last Update: 20250820T145502+0000

Ratings and Alerts

No rating or validation information has been found for APC/Cyanine7 anti-mouse CD3.

No alerts have been found for APC/Cyanine7 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. *Cancer cell*, 44(1), 203.

Mauvais FX, et al. (2025) Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors. *Immunity*, 58(4), 843.

Tang WW, et al. (2025) A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy. *Cell reports*, 44(2), 115301.

Chen ML, et al. (2025) Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production. *Cancer cell*.

Naruse C, et al. (2025) Differential substrate degradation by super-degron: EGFP in wild-type mouse cells, PD-1 requires CRBN humanization. *iScience*, 28(7), 112992.

Vitiello PP, et al. (2025) Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. *Cancer cell*, 43(7), 1296.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Mujal AM, et al. (2025) Splenic TNF- α signaling potentiates the innate-to-adaptive transition of antiviral NK cells. *Immunity*, 58(3), 585.

Xiao J, et al. (2025) Uridine depletion impairs CD8 α T cell antitumor activity through N-glycosylation. *Cell metabolism*.

Xing Y, et al. (2025) Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer. *Developmental cell*.

Kulig P, et al. (2025) Efficacy of IDOR-1117-2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis. *British journal of pharmacology*, 182(15), 3452.

Stinson JA, et al. (2025) Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control. *Molecular cancer therapeutics*, 24(1), 118.

Deliyanti D, et al. (2025) Immunotherapy with low-dose IL-2 attenuates vascular injury in mice with diabetic and neovascular retinopathy by restoring the balance between Foxp3+ Tregs and CD8+ T cells. *Diabetologia*, 68(7), 1559.

Silva Angulo F, et al. (2025) Rev-erb- α antagonism in alveolar macrophages protects against pneumococcal infection in elderly mice. *Cell reports*, 44(2), 115273.

Luan Y, et al. (2025) IgG2c subclass dominance drives fatal lupus-like nephritis via Fc γ R and complement activation. *Cell reports*, 45(1), 116775.

Pereira P, et al. (2025) Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. *Cell reports*, 44(3), 115388.

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. *STAR protocols*, 6(2), 103806.

Rodrigues PF, et al. (2025) Ror γ t-positive dendritic cells are required for the induction of peripheral regulatory T cells in response to oral antigens. *Cell*, 188(10), 2720.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

Han Y, et al. (2025) Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. *Cell*.